What SEC filings does Vaxart, Inc. submit to the SEC?

Vaxart, Inc. (VXRT) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about VXRT?

A Form 4 for VXRT discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Vaxart, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for VXRT?

The 10-K is Vaxart, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all VXRT SEC filings directly on EDGAR?

You can view all historical Vaxart, Inc. filings on the SEC EDGAR company page for VXRT. Each filing card on this page links directly to the original SEC document.

How often does Vaxart, Inc. file with the SEC?

Vaxart, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling VXRT shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

VXRT SEC Filing News — Vaxart, Inc.

Latest SEC filings for Vaxart, Inc. (VXRT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-14.

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Season…

Sector: Healthcare Industry: Biotechnology Market Cap: $115.9M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for VXRT currently lean bullish. Of the 20 displayed SEC filing records, 1 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 8 insider transactions (Form 4) in this period.

VXRT Filing Activity Snapshot 2026-05-01 — 2026-09-14

Insider Transactions (Form 4)

1 buy vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$6.5K

Watson W. Mark (Director) · 2026-05-26

10,000 shares · Form 4

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Vaxart, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 6 compensation award, 1 open-market purchase and 1 tax withholding. 1 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Tax withholding ×1: Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Form 4 Compensation award Tax / Compensation Filing 2026-07-20

VXRT insider Form 4 filed for equity award, exercise, or tax withholding

Finney Kevin (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	39,400	—	—
`A`	Compensation award derivative · Stock Options (right to buy)	78,700	—	—

Filing: Form 4 (Insider Transaction) Insider: Finney Kevin (Director) Shares: 39,400

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

VXRT insider Form 4 filed for equity award, exercise, or tax withholding

BREITMEYER JAMES B (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	8,315	—	—
`A`	Compensation award derivative · Stock Options (right to buy)	16,610	—	—

Filing: Form 4 (Insider Transaction) Insider: BREITMEYER JAMES B (Director) Shares: 8,315

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

VXRT insider Form 4 filed for equity award, exercise, or tax withholding

HERON ELAINE J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	39,400	—	—
`A`	Compensation award derivative · Stock Options (right to buy)	78,700	—	—

Filing: Form 4 (Insider Transaction) Insider: HERON ELAINE J (Director) Shares: 39,400

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

VXRT insider Form 4 filed for equity award, exercise, or tax withholding

Watson W. Mark (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	39,400	—	—
`A`	Compensation award derivative · Stock Options (right to buy)	78,700	—	—

Filing: Form 4 (Insider Transaction) Insider: Watson W. Mark (Director) Shares: 39,400

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

VXRT insider Form 4 filed for equity award, exercise, or tax withholding

Wheadon David E. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	39,400	—	—
`A`	Compensation award derivative · Stock Options (right to buy)	78,700	—	—

Filing: Form 4 (Insider Transaction) Insider: Wheadon David E. (Director) Shares: 39,400

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-26

VXRT insider Watson W. Mark (Director) bought 10,000 shares (~$6.5K)

Watson W. Mark, listed as Director at Vaxart, Inc., reported an open-market purchase of 10,000 VXRT shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	10,000	$0.65	$6.5K

Filing: Form 4 (Insider Transaction) Insider: Watson W. Mark (Director) Shares: 10,000 Est. Value: $6.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-05-21

VXRT insider Form 4 filed for equity award, exercise, or tax withholding

Grasman Jeroen Nicolaas (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	31,395	$0.61	$19.2K

Filing: Form 4 (Insider Transaction) Insider: Grasman Jeroen Nicolaas (Chief Financial Officer) Shares: 31,395

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-01

VXRT insider Form 4 filed for equity award, exercise, or tax withholding

BREITMEYER JAMES B (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	78,800	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	157,400	—	—

Filing: Form 4 (Insider Transaction) Insider: BREITMEYER JAMES B (Director) Shares: 78,800

View on SEC EDGAR → Open Filing Document →

Material Events 10 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 10 in this period for Vaxart, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-14